Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Estella M. Davis, Erin M. Uhlmeyer, David P. Schmidt & Greg L. Schardt. (2014) Strategies for Urgent Reversal of Target-Specific Oral Anticoagulants. Hospital Practice 42:5, pages 108-125.
Read now
Read now
Articles from other publishers (19)
Joseph R. Shaw, Lana A. Castellucci, Deborah Siegal & Marc Carrier. (2023) DOAC–associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature. Journal of Thrombosis and Haemostasis 21:3, pages 433-452.
Crossref
Crossref
Zeyu Guan, Roxanna Wang, Rawaa H. Hussain, James C. Fredenburgh, Iqbal H. Jaffer & Jeffrey I. Weitz. (2023) Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. Journal of Thrombosis and Haemostasis 21:1, pages 76-82.
Crossref
Crossref
Lars L. F. G. Valke, Sanna Rijpma, Danielle Meijer, Saskia E. M. Schols & Waander L. van Heerde. (2022) Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Tamana Meihandoest, Jan-Dirk Studt, Adriana Mendez, Lorenzo Alberio, Pierre Fontana, Walter A. Wuillemin, Adrian Schmidt, Lukas Graf, Bernhard Gerber, Gabriela Monika Maeder, Cédric Bovet, Thomas C. Sauter & Michael Nagler. (2021) Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Bérénice Conversy, Marie-Claude Blais, Marilyn Dunn, Carolyn Gara-Boivin & Jérôme R.E. del Castillo. (2020) Corrigendum to “Anticoagulant activity of oral rivaroxaban in healthy dogs” [Vet. J. 223 (2017) 5–11]. The Veterinary Journal 263, pages 105522.
Crossref
Crossref
Anica Petkovic, Faris Al-Khalili, Aleksandra Antovic, Majeed Ammar, Iva Pruner, Aleksandra Vranic, Nida Soutari, Nebojsa Zdravkovic, Rickard E. Malmström, Vladimir Jakovljevic & Jovan P. Antovic. (2020) Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation. Blood Coagulation & Fibrinolysis 31:4, pages 243-252.
Crossref
Crossref
Reinhard Mischke, Maike Teuber & Andreas Tiede. (2019) Measurements of endogenous thrombin potential using the CAT method in cats: Reference values and influence of the direct factor Xa inhibitor apixaban. Research in Veterinary Science 127, pages 113-121.
Crossref
Crossref
Stephanie Makhoul, Marina Panova-Noeva, Véronique Regnault, Wolfram Ruf, Philip Wenzel & Jeremy Lagrange. (2019) Rivaroxaban Effects Illustrate the Underestimated Importance of Activated Platelets in Thrombin Generation Assessed by Calibrated Automated Thrombography. Journal of Clinical Medicine 8:11, pages 1990.
Crossref
Crossref
Fakiha Siddiqui, Debra Hoppensteadt, Walter Jeske, Omer Iqbal, Alfonso Tafur & Jawed Fareed. (2019) Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum. Clinical and Applied Thrombosis/Hemostasis 25, pages 107602961984752.
Crossref
Crossref
Joseph Rigano, Cheryl Ng, Harshal Nandurkar & Prahlad Ho. (2018) Thrombin generation estimates the anticoagulation effect of direct oral anticoagulants with significant interindividual variability observed. Blood Coagulation & Fibrinolysis 29:2, pages 148-154.
Crossref
Crossref
Irina V. Gribkova, Elena N. Lipets, Irina G. Rekhtina, Alex I. Bernakevich, Dorzho B. Ayusheev, Ruzanna A. Ovsepyan, Fazoil I. Ataullakhanov & Elena I. Sinauridze. (2016) The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency. Scientific Reports 6:1.
Crossref
Crossref
S Nagalla, L Thomson, Y Oppong, B Bachman, I Chervoneva & WK Kraft. (2016) Reversibility of Apixaban Anticoagulation with a Four‐Factor Prothrombin Complex Concentrate in Healthy Volunteers. Clinical and Translational Science 9:3, pages 176-180.
Crossref
Crossref
Brian J. Dale, Noel C. Chan & John W. Eikelboom. (2016) Laboratory measurement of the direct oral anticoagulants. British Journal of Haematology 172:3, pages 315-336.
Crossref
Crossref
Armando Tripodi, Lidia Padovan, Chantarangkul Veena, Erica Scalambrino, Sophie Testa & Flora Peyvandi. (2015) How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters. Thrombosis Research 135:6, pages 1186-1190.
Crossref
Crossref
Georges Jourdi, Virginie Siguret, Anne Céline Martin, Jean-Louis Golmard, Anne Godier, Charles-Marc Samama, Pascale Gaussem, Isabelle Gouin-Thibault & Bernard Le Bonniec. (2017) Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban. Thrombosis and Haemostasis 114:07, pages 78-86.
Crossref
Crossref
Joanne van Ryn, Oliver Grottke & Henri Spronk. (2014) Measurement of Dabigatran in Standardly Used Clinical Assays, Whole Blood Viscoelastic Coagulation, and Thrombin Generation Assays. Clinics in Laboratory Medicine 34:3, pages 479-501.
Crossref
Crossref
Anita Kern, Katalin Várnai & Barna Vásárhelyi. (2014) Thrombin generation assays and their clinical application. Orvosi Hetilap 155:22, pages 851-857.
Crossref
Crossref
Gines Escolar, Victor Fernandez-Gallego, Eduardo Arellano-Rodrigo, Jaume Roquer, Joan Carles Reverter, Victoria Veronica Sanz, Patricia Molina, Irene Lopez-Vilchez, Maribel Diaz-Ricart & Ana Maria Galan. (2013) Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood. PLoS ONE 8:11, pages e78696.
Crossref
Crossref
Bérénice Conversy, Marie-Claude Blais, Marilyn Dunn, Carolyn Gara-Boivin, Lisa Carioto & Jérôme R.E. del Castillo. (2013) Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma. The Veterinary Journal 198:2, pages 437-443.
Crossref
Crossref